SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Taskinen Marja Riita) "

Search: WFRF:(Taskinen Marja Riita)

  • Result 1-2 of 2
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Rydén, Lars, et al. (author)
  • ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
  • 2013
  • In: European Heart Journal. - : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 34:39, s. 3035-3087
  • Journal article (peer-reviewed)abstract
    • This is the second iteration of the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) joining forces to write guidelines on the management of diabetes mellitus (DM), pre-diabetes, and cardiovascular disease (CVD), designed to assist clinicians and other healthcare workers to make evidence-based management decisions. The growing awareness of the strong biological relationship between DM and CVD rightly prompted these two large organizations to collaborate to generate guidelines relevant to their joint interests, the first of which were published in 2007. Some assert that too many guidelines are being produced but, in this burgeoning field, five years in the development of both basic and clinical science is a long time and major trials have reported in this period, making it necessary to update the previous Guidelines.
  •  
2.
  • van Raalte, Daniël H, et al. (author)
  • The effect of alogliptin and pioglitazone combination therapy on various aspects of beta-cell function in patients with recent-onset type 2 diabetes.
  • 2014
  • In: European journal of endocrinology / European Federation of Endocrine Societies. - 1479-683X. ; 170:4, s. 565-574
  • Journal article (peer-reviewed)abstract
    • Type 2 diabetes (T2DM) management requires continuous treatment intensification due to progressive beta-cell function decline in insulin resistant individuals. Initial combination therapy of a dipeptidyl peptidase (DPP)-4 inhibitor with a thiazolidinedione (TZD) may be rational. We assessed the effects of the DPP-4 inhibitor alogliptin (ALO) combined with the TZD pioglitazone (PIO), versus ALO monotherapy or placebo (PBO), on beta-cell function and glycemic control in T2DM.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-2 of 2

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view